Introduction: Sativex® spray is clinically utilized to deliver delta9-tetrahydrocannabinol and cannabidiol to oral mucosa for systemic absorption. We challenge the consensus that the mechanism of absorption following the oro-mucosal application occurs via the buccal tissue. Areas covered: Correctness of the consensus of this absorption pathway arose when reviewing publications regarding the influence fed versus fasting states have on pharmacokinetics of these cannabinoids administered to the oral mucosa. This finding is more suitable for peroral administration, where stomach content affects the absorption profile. We hypothesize that these cannabinoids are ingested and absorbed in the gastrointestinal tract. Expert opinion: Although clinical importance of Sativex® is not disputed, the wide acceptance of its being a successful example of drug delivery through oral mucosa is questionable. Sativex® acts as an example for other drugs delivered to oral mucosa for systemic absorption and unintentionally washed by the saliva flow into the gastrointestinal tract. Delivery of each medicine through oral mucosa should be validated in-vivo to ensure this route to be the predominant one. Revealing the underlying absorption mechanisms would enable predicting the impact of different physiological parameters such as saliva flow and fed/fasting states on the pharmacokinetics of the delivered medication.
Obidoxime Chloride is an antidote for nerve gas intoxication. As an emergency medicine, it is being stored by the Israel Defense Forces (IDF) scattered through the country of Israel in depots without a controlled environment (field conditions), thus exposed to high and fluctuating temperatures. These conditions do not meet the manufacturer′s requirements. In addition, due to possible supply shortages, the utilization of expired batches was suggested. Current work investigated these matters. Long-term (15 years) storage under different conditions was initiated. Chemical stability and toxicity in rats were assessed. No difference was found between field conditions vs the controlled environment. Obidoxime assay remained >95 % for 5 years and >90 % for seven years. pH remained above the lower specification limit for seven – eight years. The major degradation product – 4-pyridinealdoxime, surpassed the allowed limit at five years. The content of total unknown impurities reached its maximum allowed by the IDF limit at four – five years. 3-fold higher than clinically utilized doses of valid-to-date Toxogonin batches administered to rats did not cause any abnormality. However, expired batches produced significant toxic effects. While no difference was found between storage of obidoxime ampoules adhering to manufacturer′s recommendations vs field conditions, accumulation of degradants over the allowed by the IDF limit at four – five years of storage and the toxicity of the expired batches observed in rats brought the IDF to a decision of shortening the shelf-life of this product from five to four years when stored in an uncontrolled environment of the Mediterranean climate.